Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2011
07/14/2011US20110171174 Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside
07/14/2011US20110171172 Compounds for inhibiting ksp kinesin activity
07/14/2011US20110171167 Isocyanate-Based Compositions and Their Use
07/14/2011US20110171159 Glycoside Derivatives and Uses Thereof
07/14/2011US20110171157 Non-spherical fine particles, method of production thereof and cosmetic materials and resin compositions containing same
07/14/2011US20110171156 Topical Scar Treatment Composition
07/14/2011US20110171143 Method of maintaining oral health in animals
07/14/2011US20110171142 Metformin glycinate salt for blood glucose control
07/14/2011US20110171140 Absorption of therapeutic agents across mucosal membranes or the skin
07/14/2011US20110171139 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
07/14/2011US20110171138 Substantially pure deferasirox and processes for the preparation thereof
07/14/2011US20110171130 A3 adenosine receptor antagonists and partial agonists
07/14/2011US20110171127 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
07/14/2011DE102010004431A1 Pathogenesis of migraine, which is the causal therapy in the removal of perivascular edema of the dura-vascular of the brain using acetazolamide to treat migraine pain
07/14/2011CA2823974A1 Methods and compositions for the treatment of migraine headaches
07/14/2011CA2804034A1 Prodrugs of heteraromatic compounds
07/14/2011CA2790197A1 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
07/14/2011CA2786777A1 Obesity small molecules
07/14/2011CA2786686A1 Enhanced bone healing
07/14/2011CA2786603A1 Fumagillol type compounds and methods of making and using same
07/14/2011CA2786598A1 Topical transdermal dexmedetomidine compositions and methods of use thereof
07/14/2011CA2786535A1 Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
07/14/2011CA2786534A1 Arylsulfonamide pyridine-pyridinone derivatives, preparation of same, and therapeutic use thereof
07/14/2011CA2786525A1 Methods and compositions for applying moxifloxacin to the ear
07/14/2011CA2786424A1 Raf kinase inhibitors
07/14/2011CA2786328A1 Treatment method
07/14/2011CA2786319A1 Bisphenol derivatives and their use as androgen receptor activity modulators
07/14/2011CA2786289A1 Methods and compositions of targeted drug development
07/14/2011CA2786277A1 Methods and compositions of targeted drug development
07/14/2011CA2786266A1 A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
07/14/2011CA2786233A1 Anti-inflammatory analgesic adhesive patch for external use
07/14/2011CA2786072A1 Sulfone compounds as 5-ht6 receptor ligands
07/14/2011CA2786056A1 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
07/14/2011CA2786026A1 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
07/14/2011CA2785998A1 Darunavir polymorph and process for preparation thereof
07/14/2011CA2785920A1 Solid oral dosage form containing olmesartan medoxomil
07/14/2011CA2785876A1 Novel benzoic pyrrolopyridine derivatives
07/14/2011CA2785834A1 Fatty acid derivatives and analogs of drugs
07/14/2011CA2785822A1 Methods of providing weight loss therapy in patients with major depression
07/14/2011CA2785204A1 Hedgehog inhibitors
07/14/2011CA2785200A1 Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
07/14/2011CA2785037A1 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
07/14/2011CA2784921A1 Salts and crystalline forms of a factor xa inhibitor
07/14/2011CA2784908A1 Combination, kit and method of reducing intraocular pressure
07/14/2011CA2784906A1 Anti-heparin compounds
07/14/2011CA2784904A1 Methods of synthesizing factor xa inhibitors
07/14/2011CA2784772A1 Mesalamine suppository
07/14/2011CA2784744A1 Compound
07/14/2011CA2784667A1 Mglu2 agonists
07/14/2011CA2784647A1 Inhibitors of sphingosine kinase
07/14/2011CA2784601A1 Implantable device with intravesical tolerability and methods of treatment
07/14/2011CA2784580A1 Homogeneous suspension of immunopotentiating compounds and uses thereof
07/14/2011CA2784492A1 Non-irritating ophthalmic povidone-iodine compositions
07/14/2011CA2784407A1 Abuse-resistant formulations
07/14/2011CA2784118A1 Micro-rna regulation in ischemia and ischemia-reperfusion injury
07/14/2011CA2784028A1 Method of treating atrial fibrillation
07/14/2011CA2783882A1 Piperazines as antimalarial agents
07/14/2011CA2783468A1 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
07/14/2011CA2783264A1 Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
07/14/2011CA2783262A1 Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
07/14/2011CA2782366A1 Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
07/14/2011CA2782347A1 Quinoline amide m1 receptor positive allosteric modulators
07/14/2011CA2782085A1 Dp2 antagonist and uses thereof
07/14/2011CA2782075A1 Nestorone/estradiol transdermal gel
07/14/2011CA2781576A1 Combination preparation including a corticosteroid and exosomes
07/14/2011CA2781223A1 Combination preparation including a cytokine antagonist and corticosteroid
07/14/2011CA2780821A1 Mmp-13 inhibitors for the treatment of periodontitsis
07/13/2011EP2343384A2 Method for diagnosing non-small cell lung cancer
07/13/2011EP2343310A1 Serine hydrolase formulation
07/13/2011EP2343306A1 Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates
07/13/2011EP2343304A1 Biocidal boronophthalide compounds
07/13/2011EP2343303A1 PI3-kinase inhibitors
07/13/2011EP2343302A1 Tricyclic pyrazole derivatives as cannabinoid receptor modulators
07/13/2011EP2343299A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
07/13/2011EP2343298A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
07/13/2011EP2343297A1 Triazolopyridines
07/13/2011EP2343296A1 A process for the purification of paliperidone
07/13/2011EP2343295A1 Triazolopyridine derivates
07/13/2011EP2343294A1 Substituted triazolopyridines
07/13/2011EP2343293A1 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of t-cell proliferation and uses thereof
07/13/2011EP2343292A1 Novel prostaglandin i<sb>2</sb>derivative
07/13/2011EP2343291A1 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
07/13/2011EP2343290A1 Diamine derivatives as factor X inhibitors
07/13/2011EP2343289A1 Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as anti-ulcer agent
07/13/2011EP2343287A1 New 2-aminothiadiazole derivatives
07/13/2011EP2343282A1 Diaminopyrimidines as P2X3 and P2X2/3 antagonists
07/13/2011EP2343279A1 Fused-ring derivative and medical application of same
07/13/2011EP2343273A1 Novel type i natural ceramide derivative and method for producing same
07/13/2011EP2343089A1 Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naphthyridone carboxylic acid group administrated in food intended for pigs
07/13/2011EP2343088A1 Antimycotic and prebiotic pharmaceutical composition and a method for treating candidal vaginitis
07/13/2011EP2343086A2 Antibodies to CD40
07/13/2011EP2343078A1 Light-stabilized pharmaceutical composition
07/13/2011EP2343077A1 Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
07/13/2011EP2343076A1 Pharmaceutical composition for oral administration
07/13/2011EP2343075A1 Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
07/13/2011EP2343074A1 Use of purine analogues for treating airway diseases
07/13/2011EP2343073A2 Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
07/13/2011EP2343072A1 Remedy
07/13/2011EP2343071A1 Pharmaceutical dosage forms
07/13/2011EP2343070A1 Pirfenidone treatment for patients with atypical liver function